NCT01741155 2021-10-13
Study of SPI-1620 in Combination With Docetaxel Versus Docetaxel Alone for Patients With Non Small-cell Lung Cancer (NSCLC)
Spectrum Pharmaceuticals, Inc
Phase 2 Terminated
Clinical Trials
3 trialsNCT01773785 2021-10-13
Phase II Study of SPI-1620 in Combination With Docetaxel as a Second-Line to Treat Biliary Cancer
Spectrum Pharmaceuticals, Inc
Phase 2 Terminated
NCT00613691 2013-10-21
A Phase I, Open-label, Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Endothelin B Agonist, SPI-1620, in Patients With Recurrent or Progressive Carcinoma
Spectrum Pharmaceuticals, Inc
Phase 1 Completed